Latest Conference Articles

Nnena Agim, MD, presented a comprehensive update on non-steroidal topical therapies, highlighting off-label uses and recent FDA approvals in a session at the SPD's annual meeting.

Andrea Zaenglein, MD, discussed the role of patient counseling and addressing "hormone phobia" in young patients treated with hormonal therapies for acne in her SPD 2024 session.

Swanson discusses her SPD 2024 non-CME talk, expanding topical options for young patients, and more.

Catch up on coverage from the second day of the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

A significant proportion of pediatric patients with AD achieved and maintained clinical remission with dupilumab, according to a poster presented at the SPD's annual meeting.

Paller discusses her SPD 2024 lecture, "Updates from ISSVA, ESPD, and SID: What You Missed that Could Change Your Practice."

Marissa Joseph, MD, discussed inflammatory hair disorders in young children, such as CCCA, in a presentation at the SPD's annual meeting.

Caulfield discusses his SPD 2024 lecture, "The Misinformation Crisis: How Did We Get Here and What Can We Do?"

Lio discusses his SPD 2024 non-CME talk, new and exciting innovations in pediatric atopic dermatitis, and more.

Use of WoundSeal yielded no observed complications such as infection or bleeding, according to a poster presented at the SPD's annual meeting.

Catch up on coverage from the first day of the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

Hypertension and hyperlipidemia are common among obese pediatric patients with hidradenitis suppurativa, according to a poster presented at the SPD's annual meeting.

In this episode, Albert Yan, MD, FAAP, FAAD, discusses his SPD 2024 session revolving around the helpful (or hindering?) role of artificial intelligence and chatbots in dermatology.

All domains of the DLQI and CDLQI experienced improvements through 108 weeks, according to a poster presented at the SPD's annual meeting.

Silverberg discusses her SPD 2024 lecture, "Approach to Progressive Vitiligo," the future vitiligo landscape, and more.

Julapalli discusses her SPD 2024 lecture, "Rediscovering Joy in our Lives and the Workplace," excitement for the future of pediatric dermatology, and more.

The average pain score reported during treatment was 0.4/10, according to a poster presented at the SPD's annual meeting.

Mancini discusses his SPD 2024 lecture, emphasizing off-label treatments, surrogate diagnostic markers, simpler therapies, and the importance of empathy and education.

Learn more about the latest research in atopic dermatitis from Raj Chovatiya, MD, PhD, MSCI; Robert Sidbury, MD; David Rosmarin, MD; Amy Paller, MD; Melinda Gooderham, MD, MSc, FRCPC; and Jonathan Silverberg, MD, PhD, MPH.

The conference aimed at providing pediatric dermatology clinicians with the latest in the specialty begins tomorrow in Toronto, Ontario.

Ahead of the SPD's Annual Meeting in Toronto, share with us: What do you hope to learn?

Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024.

Renata Block, MMS, PA-C, and Amber Blair, MMS, PA-C, discuss the gratification of helping patients and the excitement of being on the cutting edge of research.

The post-hoc analysis evaluated the relationship between lebrikizumab serum concentration levels and sustained clinical response after lebrikizumab discontinuation.

Stephen Tyring, MD, PhD, MBA, covers the burden of antimicrobial resistance and the need for alternative treatments.

Martin Zaiac, MD, gave insight on potential risks associated with manipulation of nails, hygiene, and when it is necessary to see a specialist.

Laura Bush reflects on her term as SDPA president, discussing achievements, challenges, and the future of dermatology PAs in health care.

Rob Casquejo, PA-C, spoke with Dermatology Times on new and upcoming medications, addressing unmet needs, and social media misinformation.